文献速递心脏核医学

F-18氟吡达嗪在女性中的诊断效能:Aurora 3期试验亚组分析

Diagnostic performance of F-18 flurpiridaz in women: A sub-study of the Aurora Phase 3 trial.
PubMed 文献 · J Nucl Cardiol · 2026-01-21

该研究为Aurora 3期试验的预定义女性亚组分析,纳入188例疑似冠心病女性,在侵入性冠状动脉造影前接受F-18氟吡达嗪PET与Tc-99m SPECT检查。结果显示氟吡达嗪PET诊断显著冠心病的敏感性和特异性均达到预设主要终点,且敏感性显著高于Tc-99m SPECT,特异性非劣效。

要点

  • 氟吡达嗪PET诊断女性显著冠心病的敏感性82.9%、特异性72.8%,均达主要终点。
  • 氟吡达嗪PET敏感性显著高于Tc-99m SPECT(82.9% vs 65.9%),特异性非劣效。
  • 氟吡达嗪PET诊断确定性更高(82.4% vs 48.9%),辐射暴露更低(6.2 vs 11.2 mSv)。

核心结论

  • 在疑似冠心病女性中,F-18氟吡达嗪PET检测阻塞性冠心病的诊断效能显著高于Tc-99m SPECT。

研究设计与样本

  • Aurora 3期试验的预定义女性亚组分析,纳入188例疑似冠心病女性,在美国、加拿大和欧洲于侵入性冠状动脉造影前进行静息-负荷F-18氟吡达嗪PET与Tc-99m SPECT检查。
  • 主要终点为3名盲法阅片者多数裁决的2名专家阅片者诊断显著冠心病(狭窄≥50%)的敏感性和特异性。

主要发现

  • 氟吡达嗪PET诊断显著冠心病的敏感性为82.9%(95% CI:71.4, 94.4),P=0.0014;特异性为72.8%(95% CI:65.6, 80),P=0.0008。
  • 氟吡达嗪PET敏感性显著高于Tc-99m SPECT(82.9% vs 65.9%,差值17.1%(-1.5%, 35.6%),P=0.0448),特异性非劣效(72.8% vs 66%,差值6.8%(-3.4%, 17.0%),P=0.0004)。
  • 氟吡达嗪PET的诊断确定性显著高于Tc-99m SPECT(82.4% vs 48.9%)。
  • 氟吡达嗪PET的静息和药物负荷灌注图像质量均优于Tc-99m SPECT(P<0.0001), summed difference score显著更高(5.3 vs 3.5)。
  • 氟吡达嗪PET的辐射暴露显著低于同日静息/负荷Tc-99m SPECT(6.2 vs 11.2 mSv)。

关键数值与推荐

  • 显著冠心病定义为冠状动脉狭窄≥50%。
  • 主要终点敏感性82.9%(95% CI:71.4, 94.4),P=0.0014;特异性72.8%(95% CI:65.6, 80),P=0.0008。
  • 氟吡达嗪PET与Tc-99m SPECT敏感性差值17.1%(-1.5%, 35.6%),P=0.0448;特异性差值6.8%(-3.4%, 17.0%),P=0.0004。

临床怎么用

  • 在疑似冠心病女性中,可考虑使用F-18氟吡达嗪PET进行心肌灌注显像,以获得高于Tc-99m SPECT的诊断敏感性和图像质量。
  • 氟吡达嗪PET可提高诊断确定性并降低辐射暴露,有助于女性冠心病的无创评估。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: A recent phase 3 study of the PET perfusion tracer F-18 flurpiridaz (flurpiridaz) met the primary efficacy endpoint for the detection of CAD, demonstrating statistically higher sensitivity, non-inferior specificity compared to Tc-99m-tetrofosmin/sestamibi SPECT (Tc99m-SPECT) in the general population. This study reports a pre-specified subgroup analysis examining the diagnostic accuracy of flurpiridaz in women. METHODS: Patients with suspected CAD underwent rest-stress flurpiridaz PET and Tc99m-SPECT before invasive coronary angiography in the US, Canada, and Europe. The primary endpoint was sensitivity and specificity by 2 expert readers (majority rule between 3 blinded readers) for the diagnosis of significant CAD defined as a stenosis ≥50%. Secondary endpoints included comparison of the diagnostic performance of flurpiridaz PET and Tc99m-SPECT. RESULTS: 188 women were included in the subgroup analysis. Flurpiridaz met the pre-specified primary endpoint of sensitivity [82.9% (95% CI: 71.4, 94.4), P = 0.0014] and specificity [72.8% (95%CI: 65.6, 80),P = 0.0008]. Flurpiridaz sensitivity was significantly higher than Tc99m-SPECT [82.9% vs 65.9%, difference: 17.1% (-1.5%, 35.6%), P = 0.0448] and specificity was non-inferior [72.8% vs 66%, difference:6.8% (-3.4%, 17.0%) P = 0.0004]. Diagnostic certainty was significantly higher for women undergoing flurpiridaz PET compared to Tc99m-SPECT (82.4% v 48.9%). PET perfusion image quality was better than Tc99m-SPECT for rest and pharmacological stress images (P < 0.0001). The summed difference score was significantly higher for flurpiridaz (5.3 v 3.5). Radiation exposure was significantly lower for flurpiridaz than same day rest/stress Tc99m-SPECT (6.2 v 11.2 mSv). CONCLUSIONS: This pre-specified secondary analysis of the ARORA study in women, demonstrates high diagnostic accuracy of flurpiridaz PET to detect obstructive CAD. In women, the diagnostic performance of flurpiridaz PET for detection of CAD was significantly higher than with 99mTc-SPECT.

来源:J Nucl Cardiol,查看原文。版权归原作者所有。

引用

  1. Horgan SJ, Heller GV, Maddahi J, et al. Diagnostic performance of F-18 flurpiridaz in women: A sub-study of the Aurora Phase 3 trial. J Nucl Cardiol. 2026. PMID: 41577167. doi:10.1016/j.nuclcard.2026.102640

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。